Vistagen Announces Preliminary Positive Data in Ongoing Open-Label Extension Portion of PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
businesswire.com
⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in